A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Connor, Joseph P ^a   Cristea, Mihaela C ^b   Lewis, Nancy L ^c   Lewis, Lionel D ^d   Komarnitsky, Philip B ^e   Mattiacci, Maria R ^f,i   Felder, Mildred ^a   Stewart, Sarah ^a   Harter, Josephine ^a   Henslee Downey, Jean ^e   Kramer, Daniel ^g   Neugebauer, Roland ^g   Stupp, Roger ^h  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^e EMD SERONO INC   (United States)

^f MERCK SERONO S A   (Switzerland)

^g MERCK KGAA   (Germany)

^h UNIVERSITY OF LAUSANNE   (Switzerland)

ⁱ ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

huKS IL2; Immunocytokine; Solid tumors

Indexed keywords

CYCLOPHOSPHAMIDE; EPITHELIAL CELL ADHESION MOLECULE; TUCOTUZUMAB CELMOLEUKIN;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASCITES; BONE MARROW SUPPRESSION; BRONCHOSPASM; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; COLON CANCER; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HUMAN; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; IMMUNOGENICITY; LEUKOCYTE COUNT; LOW DRUG DOSE; LUNG CARCINOMA; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PROSTATE CANCER; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA;

AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL ADHESION MOLECULES; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84872135803     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-20     Document Type: Article

References (28)

1. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 2007, 171:386-395. 10.2353/ajpath.2007.070152, 1934518, 17600130.
2. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 2010, 31:1913-1921. 10.1093/carcin/bgq187, 20837599.
3. Connor JP, Felder M, Hank J, Harter J, Gan J, Gillies SD, Sondel P. Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. J Immunother 2004, 27:211-219. 10.1097/00002371-200405000-00005, 15076138.
4. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, Cole DJ, Gillanders WE. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004, 64:5818-5824. 10.1158/0008-5472.CAN-04-0754, 15313925.
5. Chaudry MA, Sales K, Ruf P, Lindhofer H, Winslet MC. EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. Br J Cancer 2007, 96:1013-1019. 10.1038/sj.bjc.6603505, 2360124, 17325709.
6. Kimura H, Kato H, Faried A, Sohda M, Nakajima M, Fukai Y, Miyazaki T, Masuda N, Fukuchi M, Kuwano H. Prognostic significance of EpCAM expression in human esophageal cancer. Int J Oncol 2007, 30:171-179.
7. Kim Y, Kim HS, Cui ZY, Lee HS, Ahn JS, Park CK, Park K, Ahn MJ. Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung. Anticancer Res 2009, 29:1817-1822.
8. Songun I, Litvinov SV, van de Velde CJ, Pals ST, Hermans J, van Krieken JH. Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer 2005, 92:1767-1772. 10.1038/sj.bjc.6602519, 2362035, 15870832.
9. Gastl G, Spizzo G, Obrist P, Dünser M, Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000, 356:1981-1982. 10.1016/S0140-6736(00)03312-2, 11130529.
10. MacDonald GC, Rasamoelisolo M, Entwistle J, Cizeau J, Bosc D, Cuthbert W, Kowalski M, Spearman M, Glover N. A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Des Devel Ther 2009, 2:105-114. 2761172, 19920898.
11. Mosolits S, Markovic K, Frödin JE, Virving L, Magnusson CG, Steinitz M, Fagerberg J, Mellstedt H. Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted EpCAM epitopes in colorectal carcinoma patients. Clin Cancer Res 2004, 10:5391-5402. 10.1158/1078-0432.CCR-04-0425, 15328177.
12. Schanzer JM, Fichtner I, Baeuerle PA, Kufer P. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to EpCAM expressing tumor cells. J Immunother 2006, 29:477-488. 10.1097/01.cji.0000210080.60178.fd, 16971804.
13. Ruf P, Gires O, Jäger M, Fellinger K, Atz J, Lindhofer H. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 2007, 97:315-321. 10.1038/sj.bjc.6603881, 2360319, 17622246.
14. Salnikov AV, Groth A, Apel A, Kallifatidis G, Beckermann BM, Khamidjanov A, Ryschich E, Büchler MW, Herr I, Moldenhauer G. Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma. J Cell Mol Med 2009, 13:4023-4033. 10.1111/j.1582-4934.2009.00723.x, 20196789.
15. Richter CE, Cocco E, Bellone S, Silasi DA, Rüttinger D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Am J Obstet Gynecol 2010, 203:582. e1-7, 2993821, 20870202.
16. Patriarca C, Macchi RM, Marschner AK, Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 2012, 38:68-75. 10.1016/j.ctrv.2011.04.002, 21576002.
17. Johnson EE, Lum HD, Rakhmilevich AL, Schmidt BE, Furlong M, Buhtoiarov IN, Hank JA, Raubitschek A, Colcher D, Reisfeld RA, Gillies SD, Sondel PM. Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunol Immunother 2008, 57:1891-1902. 10.1007/s00262-008-0519-0, 2574976, 18438664.
18. Holden SA, Lan Y, Pardo AM, Wesolowski JS, Gillies SD. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin Cancer Res 2001, 7:2862-2869.
19. Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, Kovar A, Dahl T, Gillies SD. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J Immunother 2004, 27:232-239. 10.1097/00002371-200405000-00008, 15076141.
20. Thompson JA, Lee DJ, Cox WW, Lindgren CG, Collins C, Neraas KA, Dennin RA, Fefer A. Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. Cancer Res 1987, 47:4202-4207.
21. King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, Eickhoff J, Kendra K, Reisfeld R, Gillies SD, Sondel P. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol 2004, 22:4463-4473. 10.1200/JCO.2004.11.035, 2367368, 15483010.
22. Ribas A, Kirkwood JM, Atkins MB, Whiteside TL, Gooding W, Kovar A, Gillies SD, Kashala O, Morse MA. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. J Transl Med 2009, 7:68. 10.1186/1479-5876-7-68, 2724499, 19640287.
23. Quan WD, Quan FM, King LA, Walker PR. Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. Cancer Biother Radiopharm 2008, 23:108-113. 10.1089/cbr.2007.0420, 18298334.
24. Freeman SM, Franco JL, Kenady DE, Baltzer L, Roth Z, Brandwein HJ, Hadden JW. A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. Am J Clin Oncol 2011, 34:173-178.
25. Singh H, Hilf N, Mendrzyk R, Maurer D, Weinschenk T, Kirner A, Frisch J, Reinhardt C, Stenzl A, Walter S. Correlation of immune responses with survival in a randomized phase II study investigating multipeptide vaccination with IMA901 plus or minus low-dose cyclophosphamide in advanced renal cell carcinoma (RCC). J Clin Oncol 2010, 28(suppl):abstract 2587.
26. Lindemann A, Höffken K, Schmidt RE, Diehl V, Kloke O, Gamm H, Hayungs J, Oster W, Böhm M, Kolitz JE. A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma. Cancer Immunol Immunother 1989, 28:275-281.
27. Alderson KL, Sondel PM. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol 2011, 2011:379123. 3110303, 21660134.
28. Sondel PM, Gillies SD. Current and potential uses of immunocytokines as cancer immunotherapy. Antibodies 2012, 1:149-171.